Company Profile
Morphic Therapeutic
Company Overview
Morphic Therapeutic is leading the development of a new generation of oral integrin drugs.
Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders and immuno-oncology.
Morphic was created in 2015 with support from Timothy Springer, PhD, Polaris Partners, Schrödinger Inc., and ShangPharma. New investors SROne, Pfizer Ventures, Omega Funds and AbbVie joined for the Series A round in June 2016.
In September 2018, Morphic Therapeutic completed a $80 million Series B financing round to advance multiple programs into the clinic. The round was co-led by Omega Funds and Novo Holdings, along with new investors Invus and EcoR1 Capital, in addition to Morphic’s Series A investors.